Gliclazide improves anti‐oxidant status and nitric oxide‐mediated vasodilation in type 2 diabetes
D Fava, M Cassone‐Faldetta, O Laurenti… - Diabetic …, 2002 - Wiley Online Library
D Fava, M Cassone‐Faldetta, O Laurenti, O De Luca, A Ghiselli, G De Mattia
Diabetic medicine, 2002•Wiley Online LibraryAims To evaluate the effects of gliclazide on oxidative status and vascular response to
systemic administration of L‐arginine, the natural precursor of nitric oxide (NO), in Type 2
diabetic patients. Methods Thirty Type 2 diabetic patients received glibenclamide (n= 15) or
gliclazide (n= 15) in a 12‐week, randomized, observer‐blinded, parallel study. Plasma lipid
peroxides, total radical‐trapping anti‐oxidant parameter (TRAP), and blood pressure
responses to an intravenous bolus of L‐arginine were measured pre‐and post‐treatment …
systemic administration of L‐arginine, the natural precursor of nitric oxide (NO), in Type 2
diabetic patients. Methods Thirty Type 2 diabetic patients received glibenclamide (n= 15) or
gliclazide (n= 15) in a 12‐week, randomized, observer‐blinded, parallel study. Plasma lipid
peroxides, total radical‐trapping anti‐oxidant parameter (TRAP), and blood pressure
responses to an intravenous bolus of L‐arginine were measured pre‐and post‐treatment …
Abstract
Aims To evaluate the effects of gliclazide on oxidative status and vascular response to systemic administration of L‐arginine, the natural precursor of nitric oxide (NO), in Type 2 diabetic patients.
Methods Thirty Type 2 diabetic patients received glibenclamide (n = 15) or gliclazide (n = 15) in a 12‐week, randomized, observer‐blinded, parallel study. Plasma lipid peroxides, total radical‐trapping anti‐oxidant parameter (TRAP), and blood pressure responses to an intravenous bolus of L‐arginine were measured pre‐ and post‐treatment.
Results At 12 weeks, gliclazide patients had lower plasma lipid peroxides (13.3 ± 3.8 µmol/l vs. 19.2 ± 4.3 µmol/l; P = 0.0001) and higher plasma TRAP (1155.6 ± 143.0 µmol/l vs. 957.7 ± 104.3 µmol/l; P = 0.0001) than the glibenclamide patients. Gliclazide but not glibenclamide significantly reduced systolic and diastolic blood pressure (P = 0.0199 and P = 0.00199, respectively, two‐way repeated measures analysis of variance) in response to intravenous L‐arginine.
Conclusions Gliclazide reduces oxidative stress in Type 2 diabetic patients by improving plasma anti‐oxidant status. This effect is associated with enhanced NO‐mediated vasodilation.
Wiley Online Library